Herombopag promotes platelet engraftment and decreases platelet transfusion after allogeneic hematopoietic stem cell transplantation. (20th January 2023)

• Record Type: Journal Article
• Authors: Zheng, Xinhui; Zhang, Haixiao; Guo, Wenwen; Cao, YiGeng; Liu, Xin; Zhai, WeiHua; Zhang, Xiaoyu; Wang, Fengjiao; Wei, JiaLin; Yang, DongLin; Huang, Yong; Pang, AiMing; Feng, SiZhou; Jiang, ErLie; Han, MingZhe
• Is Part Of: European journal of haematology. Volume 110:Number 5(2023)
• Page Start: 527
• Page End: 533
• Publication Date: 2023-01-20
• Subjects: delayed platelet engraftment -- engraftment -- hematopoietic stem cell transplantation -- herombopag -- thrombopoietin‐receptor agonist; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; Blood -- Periodicals; 616.15005
• DOI: 10.1111/ejh.13925
• Languages: English
• ISSNs: 0902-4441

Abstract

Abstract: The delayed platelet engraftment associated with allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is a common complication and often results in increased transplant‐related complications. A single‐center, prospective, investigator‐initiated pilot study was conducted to explore whether herombopag, a second generation thrombopoietin‐receptor agonist, would promote platelet engraftment after allo‐HSCT. Between 2/2022 and 06/2022, 17 individuals (median age 39; range 15–58 years) with hematological malignancies were enrolled. Herombopag was given for a median of 22 (range 14–61) days at a dose of 7.5 mg/d. The median time to neutrophil >500/μl was 11 (range 9–19) days. The median time to platelet >20 000/μl and >50 000/μl was 13 (range 8–22), and 20 (range 14–45) days, respectively. Compared with historical controls, the cumulative incidence of platelet engraftment after HSCT was significantly higher in the herombopag group (>20 000/μl at day +21, 88% vs 65%, p = .003; >50 000/μl at day +30, 65% vs. 43%, p = .001). Herombopag also reduced the units of platelet transfusion within 30 days post‐SCT (3.6 ± 2.5 vs. 5.4 ± 3.2 U, p = .01). In conclusion, it seems likely that herombopag could enhance platelet engraftment after allo‐HSCT.